Ergomed, a company dedicated to the provision of specialized services to the pharmaceutical industry and the development of new drugs, announced the strengthening of its executive team with the appointment of Dr. Dan Weng as its new chief executive officer and a board director of Ergomed. Dr. Weng joins Ergomed with effect from 1 July 2017 from EPS Holdings (EPSHD), a global CRO listed on the Tokyo Stock Exchange.

When Dr. Weng joins the company, Dr. Miroslav Reljanovic, Ergomed’s founder, will transition from CEO to executive vice-chairman, where he will support Dr. Weng and the board in growing and developing Ergomed’s CRO offering and provide strategic guidance on Ergomed’s co-development business and wholly-owned pipeline.

Dr. Weng has extensive experience in managing and growing CRO businesses, including nearly six years at EPS International Holding (EPSI), subsidiary of EPSHD, where he was chairman, president and CEO. During his tenure at EPSI, Dr. Weng oversaw significant growth, both organically and through M&A in Asia, the U.S. and Europe, with revenues increasing over five-fold. Dr. Weng’s background covers multiple therapeutic areas, supporting all stages of development through to approval. He was also a board director of EPSHD and had an active role in corporate strategy and investor relations.

Prior to this, Dr. Weng has a proven track record with 20 years of delivering growth in executive positions at international CROs including MedPace, Icon Clinical Research, PharmaNet and Quintiles, where he established the offering in China.

Dr. Weng qualified as a medical doctor at Tongji Medical University, China, and holds an MA in Health Planning, Policy and Management from the University of Leeds, U.K. He also held research positions at Harvard Medical School, Massachusetts General Hospital and the University of California.

Reljanovic said: “Ergomed has a history of innovation in clinical research and development and this is set to continue. I’m very pleased to welcome Dan to the team to guide Ergomed forward as we seek to build on the strong growth of our CRO and pharmacovigilance businesses. I look forward to contributing to Ergomed’s continued success as Vice-Chairman, focusing on our existing and future co- development deals, our pipeline products, and the broader strategy of the business.”

Peter George, chairman of Ergomed, said: “Dan has significant experience in growing CRO businesses globally, and is an ideal addition to the Ergomed team. With the increasing maturity and scale of the business, his international experience in corporate development across all the areas of clinical research make for an excellent fit.